Oxford BioMedica could pocket $100m on Novartis CAR-T cell success – BioPharma-Reporter.com
BioPharma-Reporter.com |
Oxford BioMedica could pocket $100m on Novartis CAR–T cell success
BioPharma-Reporter.com The US approval of the first autologous chimeric antigen receptor (CAR) T cell therapy Kymriah (tisagenlecleucel) has been heralded as a historic moment in cancer treatment, and at a price of $475,000 (€400,000) for a one-time infusion, is set to … |
